Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336679 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL1335372 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL1334598 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL1336011 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL1336008 | 0.84 | DPP4 (0.34) | DPP4DPP8DPP9PEPDXPNPEP1 | |
| SCHEMBL1493709 | 0.84 | PIN1 (0.40) | PIN1CNR2DPP4DPP8DPP9 | |
| SCHEMBL12757999 | 0.84 | PIN1 (0.40) | PIN1CNR2DPP4DPP8DPP9 | |
| SCHEMBL3725157 | 0.83 | PIN1 (0.40) | PIN1CNR2DPP4DPP8DPP9 | |
| SCHEMBL5502343 | 0.83 | PIN1 (0.40) | PIN1CNR2DPP4DPP8DPP9 | |
| SCHEMBL10110426 | 0.83 | PIN1 (0.42) | PIN1CNR2DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | PIN1 4600/4885CNR2 153/4885DPP4 2412/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | PIN1 804/4885CNR2 1934/4885DPP4 1/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | PIN1 2350/4885CNR2 46/4885DPP4 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.